The California-based Iovance Biotherapeutic is expanding to the Philadelphia Navy Yard in South Philadelphia to build a 136,000 square foot office, lab, and production facility.
“We know there are certainly trained employees in the region who have worked in cell therapy and have deep roots in cell therapy,” said Maria Fardis, the president and chief executive of Iovance.
Iovance specializes in the development and commercialization of cancer immunotherapies using cells known as tumor-infiltrating lymphocytes.
Construction for the $125 million facility is expected to last two years. Iovance plans to employ several hundreds of people while producing treatments for thousands of patients globally.
Article by the Philadelphia Inquirer